Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Kalow

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
The Pharmacogenomics Journal|March 23, 2002
Multigenic traits and risk assessment in pharmacology: a population approachW Kalow, V Ozdemir, L Tothfalusi
Research Communications in Chemical Pathology and Pharmacology|July 1, 1981
Identification of p(4')-hydroxyantipyrine as a metabolite of antipyrine in manT Inaba, H Uchino, W Kalow
Clinical Pharmacology and Therapeutics|December 1, 1976
Genetic study of amobarbital elimination based on its kinetics in twinsL Endrenyi, T Inaba, W Kalow
Pharmacogenetics|December 1, 1991
Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscleW Kalow, S Sharer, B Britt
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 1, 1983
Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl groupH Uchino, T Inaba, W Kalow
Journal of Pharmacobio-Dynamics|March 1, 1984
Metabolism of 14C-iodochlorhydroxyquin in the dog and the ratM Jurima, W Kalow, T Inaba
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1985
Mephenytoin metabolism in vitro by human liverM Jurima, T Inaba, W Kalow
Canadian Anaesthetists' Society Journal|November 1, 1977
The caffeine test of isolated human muscle in relation to malignant hyperthermiaW Kalow, B A Britt, A Richter
Life Sciences|February 14, 1983
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsS V Otton, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|February 1, 1981
Debrisoquine hydroxylation capacity: problems of assessment in two populationsT Inaba, S V Otton, W Kalow
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
The Pharmacogenomics Journal|March 23, 2002
Multigenic traits and risk assessment in pharmacology: a population approachW Kalow, V Ozdemir, L Tothfalusi
Research Communications in Chemical Pathology and Pharmacology|July 1, 1981
Identification of p(4')-hydroxyantipyrine as a metabolite of antipyrine in manT Inaba, H Uchino, W Kalow
Clinical Pharmacology and Therapeutics|December 1, 1976
Genetic study of amobarbital elimination based on its kinetics in twinsL Endrenyi, T Inaba, W Kalow
Pharmacogenetics|December 1, 1991
Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscleW Kalow, S Sharer, B Britt
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 1, 1983
Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl groupH Uchino, T Inaba, W Kalow
Journal of Pharmacobio-Dynamics|March 1, 1984
Metabolism of 14C-iodochlorhydroxyquin in the dog and the ratM Jurima, W Kalow, T Inaba
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1985
Mephenytoin metabolism in vitro by human liverM Jurima, T Inaba, W Kalow
Canadian Anaesthetists' Society Journal|November 1, 1977
The caffeine test of isolated human muscle in relation to malignant hyperthermiaW Kalow, B A Britt, A Richter
Life Sciences|February 14, 1983
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsS V Otton, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|February 1, 1981
Debrisoquine hydroxylation capacity: problems of assessment in two populationsT Inaba, S V Otton, W Kalow
Pageof 19